• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 3. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 4. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

• Solvents and Organic Chemicals Organic Compounds Acids/Esters
• Catalysts and Inorganic Chemicals Inorganic Compounds Salt

Introduction to Cyclamic acid sodium (CAS No: 139-05-9)

Cyclamic acid sodium, with the chemical formula NaC?H?NO?, is a sodium salt derivative of cyclamic acid, a compound that has garnered significant attention in the field of pharmaceuticals and biotechnology due to its versatile applications. This compound, identified by its unique Chemical Abstracts Service (CAS) number 139-05-9, is widely recognized for its role as an intermediate in the synthesis of various pharmacologically active molecules. The introduction of sodium cyclamate into pharmaceutical formulations has opened new avenues for therapeutic interventions, particularly in the management of metabolic disorders and as a flavor enhancer in food products.

The structure of Cyclamic acid sodium consists of a sodium ion (Na?) paired with the cyclamic acid anion, which features a six-membered heterocyclic ring containing a carboxylate group and an amide moiety. This structural configuration imparts unique chemical properties that make it an invaluable component in drug design and development. The compound’s solubility in water and stability under various pH conditions further enhance its utility in pharmaceutical formulations, making it an attractive candidate for oral and injectable medications.

In recent years, research has highlighted the potential of Cyclamic acid sodium as a key intermediate in the synthesis of novel therapeutic agents. For instance, studies have demonstrated its role in the development of inhibitors targeting enzymes involved in glucose metabolism. These inhibitors are particularly relevant in the context of diabetes management, where modulating glucose uptake and utilization is crucial. The ability of Cyclamic acid sodium to interact with biological targets without exhibiting significant toxicity has positioned it as a promising candidate for further clinical investigation.

Moreover, the compound has been explored for its anti-inflammatory properties. Emerging research suggests that derivatives of cyclamic acid may inhibit the activity of inflammatory cytokines, thereby reducing inflammation and associated symptoms. This has opened up possibilities for the development of new treatments for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. The structural versatility of cyclamic acid derivatives allows for modifications that can enhance their efficacy and selectivity, making them more suitable for therapeutic applications.

The use of Cyclamic acid sodium in food technology is another area where its significance is well-documented. Cyclamates, including sodium cyclamate, are used as artificial sweeteners due to their high sweetness intensity with minimal aftertaste. They are particularly valued for their stability under heat treatment, making them suitable for use in baked goods and processed foods. Despite some controversies regarding their safety, regulatory bodies around the world have approved their use within specified limits, recognizing their potential benefits over traditional sugar-based sweeteners.

The synthesis of Cyclamic acid sodium typically involves the reaction of phthalic anhydride with ammonia or ammonium hydroxide, followed by neutralization with sodium hydroxide to yield the sodium salt. This synthetic route is efficient and scalable, allowing for large-scale production needed to meet industrial demands. Advances in synthetic methodologies have further optimized this process, reducing waste generation and improving yield rates. Such improvements are crucial for ensuring sustainable production practices align with environmental regulations.

The pharmacokinetic profile of Cyclamic acid sodium has been extensively studied to understand its absorption, distribution, metabolism, and excretion (ADME) characteristics. Research indicates that it is well-absorbed following oral administration and exhibits moderate bioavailability. Its metabolism primarily involves hydrolysis followed by renal excretion, which suggests that it can be safely used in patients with varying degrees of renal function. These findings are essential for determining appropriate dosing regimens and minimizing potential side effects.

In conclusion, Cyclamic acid sodium (CAS No: 139-05-9) is a multifaceted compound with significant applications in pharmaceuticals and food technology. Its role as an intermediate in drug synthesis, along with its potential therapeutic benefits in managing metabolic disorders and inflammation, underscores its importance in modern medicine. Additionally, its use as a food sweetener highlights its versatility beyond healthcare applications. As research continues to uncover new uses and refine synthetic methods, the importance of this compound is likely to grow further.

• 139-06-0(calcium bis(N-cyclohexylsulfamate))
• 68476-78-8(Molasses)
• 61517-51-9(Sulfamic acid, (1-ethylbutyl)-)
• 78699-31-7(Sulfamic acid, bicyclo[2.2.1]hept-2-yl-, monosodium salt, exo- (9CI))
• 100-88-9(Cyclamic acid)
• 20504-34-1(Sulfamic acid, N-cyclopentyl-, sodium salt (1:1))
• 5897-16-5(Calcium Cyclamate Dihydrate)
• 61517-52-0(Sulfamic acid, (1-propylbutyl)-)
• 64011-64-9(Sulfamic acid,N-cyclohexyl-, barium salt (1:?))
• 6282-74-2(Sulfamic acid, N-cyclohexyl-,barium salt (2:1))